Technical Analysis for RVX - Resverlogix Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% |
| Alert | Time |
|---|---|
| Reversed from Up | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Up 1 ATR | 1 day ago |
| 50 DMA Resistance | 1 day ago |
| 20 DMA Resistance | 1 day ago |
Get a Trading Assistant
- Earnings date: 2024-06-27
Resverlogix Corp. Description
Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Beta Clinic Biotechnology Disease RTT Medical Specialties Diseases Clinical Trial IPO Diabetes Alzheimer's Disease Chronic Condition Chronic Kidney Diabetes Mellitus Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.115 |
| 52 Week Low | 0.04 |
| Average Volume | 29,337 |
| 200-Day Moving Average | 0.062 |
| 50-Day Moving Average | 0.054 |
| 20-Day Moving Average | 0.052 |
| 10-Day Moving Average | 0.052 |
| Average True Range | 0.004 |
| RSI (14) | 42.20 |
| ADX | 16.06 |
| +DI | 35.714 |
| -DI | 23.929 |
| Chandelier Exit (Long, 3 ATRs) | 0.048 |
| Chandelier Exit (Short, 3 ATRs) | 0.052 |
| Upper Bollinger Bands | 0.058 |
| Lower Bollinger Band | 0.046 |
| Percent B (%b) | 0.33 |
| BandWidth | 22.308 |
| MACD Line | -0.001 |
| MACD Signal Line | 0.000 |
| MACD Histogram | -0.0003 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.050 | ||||
| Resistance 3 (R3) | 0.050 | 0.050 | 0.050 | ||
| Resistance 2 (R2) | 0.050 | 0.050 | 0.050 | 0.050 | |
| Resistance 1 (R1) | 0.050 | 0.050 | 0.050 | 0.050 | 0.050 |
| Pivot Point | 0.050 | 0.050 | 0.050 | 0.050 | 0.050 |
| Support 1 (S1) | 0.050 | 0.050 | 0.050 | 0.050 | 0.050 |
| Support 2 (S2) | 0.050 | 0.050 | 0.050 | 0.050 | |
| Support 3 (S3) | 0.050 | 0.050 | 0.050 | ||
| Support 4 (S4) | 0.050 |
